HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Aloj, L. Articles by Eckelman, W. C. Search for Related Content PubMed PubMed Citation Articles by Aloj, L. Articles by Eckelman, W. C.

Targeting of Transferrin Receptors in Nude Mice Bearing A431 and LS174T Xenografts with [¹⁸F]Holo-Transferrin: Permeability and Receptor Dependence

Nuclear Medicine and PET Departments, Clinical Center
Bioengineering and Physical Science Program, Office of Research Services, National Institutes of Health, Bethesda, Maryland

Correspondence: For correspondence or reprints contact: Luigi Aloj, MD, Centro di Studio per la Medicina Nucleare, Consiglio Nazionale delle Ricerche, c/o Dipartimento di Scienze Biomorfologiche e Funzionali, Universita' degli Studi di Napoli "Federico II", Via S. Pansini 5, 80131, Napoli, Italy.

ABSTRACT

The goal of this study was to investigate whether ¹⁸F-labeled transferrin (Tf), which has a molecular weight (M_r) of 79,000, binds to Tf receptor sites in tumors in a specific manner within the time frame commensurate with the half-life of ¹⁸F (109.7 min). We have previously shown that [¹⁸F]holo-Tf ([¹⁸F]Tf) maintains all properties of native Tf in vitro and that it can specifically target liver Tf receptor sites in vivo. Methods: Theb distribution of [¹⁸F]Tf, using [¹⁸F]albumin (Alb) or [¹⁴C]Alb as a control, was studied over a 6-h period in nude mice bearing LS174T and A431 xenografts of a high- and low-permeability tumor, respectively. Results: Measurements of Tf receptor concentration in the tumor extracts suggest similar binding capacities. In vivo, liver uptake values were higher for [¹⁸F]Tf than for both [¹⁸F]Alb and [¹⁴C]Alb throughout the study, indicating specific binding. In contrast, tumor Tf uptake values remained below those of the Alb tracers, and tumor-to-blood ratios of [¹⁸F]Tf in each xenograft increased in parallel with those of the Alb tracers. The permeabilities of [14C]Alb and [¹⁸F]Tf in LS174T were calculated to be 1.29 ± 0.49 and 1.03 ± 0.38 µL/min/g (mean ± SD), respectively, whereas the permeabilities of the two tracers in A431 were 0.79 ± 0.24 and 0.44 ± 0.04 µL/min/g. Pharmacokinetic modeling of the data using these permeabilities and the high plasma and extracellular concentrations of endogenous Tf showed that the observed uptake values in the two xenografts are consistent with a non-receptor—mediated distribution. In the liver, the absence of permeability barriers yields specific [¹⁸F]Tf binding to receptors compared with the [¹⁴C]Alb control, within 5 min after injection. Conclusion: Receptor-mediated accumulation of [¹⁸F]Tf in tumor xenografts is impaired by rate-determining permeability and competition from endogenous Tf and is not achieved in a time frame of 6h.

Key Words: transferinn • ¹⁸F • neoplasms • pharmacokinetics • liver